DOCSLIB.ORG

YEREVAN STATE MEDICAL UNIVERSITY AFTER M. HERATSI DEPARTMENT of PHARMACY Balasanyan M.G. Zhamharyan A.G. Afrikyan Sh. G. Khachat

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
YEREVAN STATE MEDICAL UNIVERSITY AFTER M. HERATSI DEPARTMENT of PHARMACY Balasanyan M.G. Zhamharyan A.G. Afrikyan Sh. G. Khachat YEREVAN STATE MEDICAL UNIVERSITY AFTER M. HERATSI DEPARTMENT OF PHARMACY Balasanyan M.G. Zhamharyan A.G. Afrikyan Sh. G. Khachaturyan M.S. Manjikyan A.P. MEDICINAL CHEMISTRY MANUAL (part 2) YEREVAN 2020 1 LOCAL ANESTHETICS Similar to many modern drugs, the initial leads for the design of clinically useful local anesthetics (LA) were derived from natural sources. Since 15th century it was known that Erythroxylon Coca plant leaves possess anesthetic properties. The active principle of the coca leaf however was not discovered until 1860 by Niemann, who obtained a crystalline alkaloid from the leaves, to which he gave the name cocaine. Koller introduced cocaine into clinical practice in 1884 as a topical anesthetic for ophthalmological surgery. After cocaine releasing, discovering the structure and synthesis, became clear that it represents methyl ecgonine benzoate, which is easily hydrolyzed (especially during sterilization in high temperature), forming ecgonine, benzoic acid and methanol. COOCH3 N CH3 O C O Cocaine had one big disadvantage: its toxicity was very high. Studies of the cocaine biological activity and its hydrolysis products have shown that local anesthetic activity is due to anesthesiophor group, which includes the following structural parts: 1. aromatic ring (with radicals), which gives lipophilic properties to the molecule, 2. aliphatic amino group, which is responsible for the molecule’s hydrophilic properties, 3. intermediate chain, which connects molecule’s lipophilic and hydrophilic components. Chemically it represents benzoic acid connected with different groups (Rs-different aliphatic radicals) by ester, amide or thio ether bonds (X=O, NH, S). R''' R' Ar C X (C)n N R'' O R'''' Each of this components’ role have been studied on the anesthetic activity. It becomes clear, that the aromatic ester group is so important; scientists thought that all aromatic esters have an anesthetic activity. Therefore, many derivatives of benzoic acid have been synthesized, majority 2 of which possess high anesthetic activity and low toxicity. Anesthesin is an example of this group, which represents ethyl ester of para-amino benzoic acid (PABA). O H2N C O C2H5 Anesthesin This compounds’ disadvantage is that practically used their soluble salts possess strong acidic reaction, in which result they are used in form of water insoluble bases, which can’t be used for infiltration or transmitting anesthesia and can be used only for superficial anesthesia, in powders, ointments forms for ulcers, burns and mucous inflammation anesthesia. Having a goal to increase PABA alkyl ethers water solubility, tertiary amino group inserted in the molecule alcoholic part. This amino group insertion increases these ethers basic properties, giving chance to get salts, solutions of which don’t have acidic reaction, but it’s near to basic. Besides, tertiary amino group insertion in the ester’s molecule increases their anesthetic properties. PABA diethylamino ethanolic ester hydrochloride (designed according to this principle) is well known in literature under Novocain or procaine names. Novocain also has anesthesiophor group, but it is not free from side effects: it has anti-sulfanilamide effect, causes allergic reactions. Its local anesthetic effect is quite short and it can’t be used for superficial anesthesia. Due to these reason new local anesthetics synthesis continues and doesn’t stop. O C2H5 .HCl H2N C O CH2 CH2N C2H5 Novocain It was very important to study interaction types between Novocain and its corresponding receptor for new local anesthetics synthesis. It was found, that there are different bonds between receptor centers and molecule different parts (charge transfer: induced dipole, dipole-dipole interaction, hydrogen bond, van der Waals interactions and hydrophobic interaction and ionic bond). 3 SAR Changes in the aromatic ring In all local anesthetics as in Novocain carbonyl group’s activity and binding force with the receptor depends on carbon atom partly positive charge, due to which conjugation is possible between double bond’s π-electronic cloud and aromatic ring π framework to delocalize toward carbonyl group carbon atom. Insertion of an electron-donating substituent in the aromatic ring increases carbon atom partly positive charge, due to which binding with the receptor is stronger which leads to stronger local anesthetics effect. Electron acceptor substituent (for example nitro group) decreases or loses local anesthetic property. Insertion of a methylene group between the aromatic moiety and carbonyl function is undesirable. 4 Local anesthetic activity increases in case of amino group presence in the para-position of the aromatic ring (Novocain). NH2 substitution by NHR or NR2: anesthetic activity increases when R extends up to C3; C3-C6 activity remains and more than C6 sharply decreases. According to this Dicaine was created, which represents dimethylamino ethyl ester of para-butylamino benzoic acid. Dicaine Changes in the intermediate chain The distance between ester oxygen and amino group’s nitrogen is very important for the local anesthetic activity, which is detected by the carbon atoms number in the alcohol chain. The elongations and branching of this chain increase local anesthetic activity, also toxicity (local, general) sharply increases. Local anesthetic activity increases also in cyclic group presence in this part, but these compounds are not used either, because they have strong irritative properties. Corresponding amides are obtained substituting ester oxygen by NH, the most of which show higher activity, than isosteric esters, but their toxicity also is high. From these compounds Sovcain is used, but it requires great caution because of high toxicity. C2H5 O NH CH 2 CH2 N C C2H5 N OC4H9 Sovcain 5 Novocain’s corresponding isosteric amide, which is known under the name of Novocainamide has low expressed local anesthetic activity, but has very high anti-arrhythmic effect. Novocain thioisoster - Thiocain has 3 times higher local anesthetic activity. O O C C2H5 C C2H5 NH CH 2 CH2 N S CH 2 CH2 N C2H5 C2H5 H2N H2N Novocainamide Thiocain Changes in the aliphatic amino group Chain elongation increases local anesthetic effect and local irritative property. Branching decreases toxicity, and local anesthetic effect. Cyclic radicals were inserted; nitrogen in a cycle, etc. Tertiary amino group can be represented in heterocycle. Benzoic and para-amino benzoic esters were studied which contain heterocyclic radicals, such as pyrrole, pyrroline, piperidine, piperazine etc. Piperidine derivatives are the most interesting. Benzoate methylpiperidinpropanol- meticain is one of the strongest local anesthetics now. H2C CH2 CO O CH2 CH 2 CH2 N CH2 CH CH2 H3C Meticain Amino acids amides are very interesting from which lidocaine has expressed local anesthetic effect, which is known as xylocaine. Lidocaine Trimecaine Action Mechanism Local anesthetics prevent nerve impulse formation and transmission. They block sodium channels, inhibit action potential formation and nervous impulse isn’t transmitted. Now it is known that there are specific receptors in the sodium channels, to which local anesthetics are bound. 6 Way of reaching to the receptor depends on their physico-chemical properties: molecule size, pK, solubility and binding by the chemical properties. Protonized molecules and quaternary ammonium compounds reach to their targets through the external hydrophilic way, which is possible only during channel activation. Lipophilic anesthetics are diffused across the nerve membrane in basic, uncharged state. They can reach to the receptor immediately: in their basic uncharged form- by hydrophobic way, also they can bind with medium protons and reach to the receptor after protonization - by hydrophilic way. There is a hypothesis, according to which local anesthetics receptors represent acidic phospholipids, to which local anesthetics bind (especially with lecithin). Let’s study that binding for Novocain and receptor example; it is carried out: a) via ion –dipole interaction, where ionic group and polarized group take part in the bond formation. b) via hydrophobic bond where lipophilic groups take part. Hydrogen bonds are also formed, the stronger is the bond the longer is local anesthetic effect. It is known, that local anesthetics compete with Ca, which binding with the acidic phospholipids regulates sodium permeability through the nervous membrane. Local anesthetics forming mentioned above bonds displace Ca, causing cellular membrane structural and functional changes and impulse transmission is inhibited. A lot of local anesthetics can form a π-complex with thiamine, where the anesthetic appears as an electro donor and thiamin as an acceptor. As it is known, thiamin and its precursors (phosphate ethers) have fundamental importance in nerve excitability. Local anesthetics forming thiamine complex, block nervous transmission and develop local anesthesia. 7 Classification All local anesthetics can be divided into 2 groups: Ester derivatives. There are esters of the following acids: benzoic acid, para-amino benzoic acid, meta-amino benzoic acid or para-alkoxy benzoic acid. As esters drugs of this group easily undergo hydrolysis in vivo and in vitro losing their activity. More common classification is: a) benzoic acid derivatives, cocaine, isobucaine, pribecaine, propanocaine, etc. b) amino benzoic acid derivatives, betoxycain, novocain, tetracaine, benzocaine, etc. Amide derivatives. This group includes 3 subgroups: a) basic amides - dibucaine,
Load more

Recommended publications
  • (12) United States Patent (10) Patent No.: US 8,148,546 B2 Schuster Et Al
    US008148546B2 (12) United States Patent (10) Patent No.: US 8,148,546 B2 Schuster et al. (45) Date of Patent: Apr. 3, 2012 (54) TETRAHYDROCARBAZOLE DERIVATIVES (58) Field of Classification Search .................. 548/448: ASLGANDS OF G-PROTEIN COUPLED 51474 11 RECEPTORS See application file for complete search history. (75) Inventors: Tilmann Schuster, Grossostheim (DE); Klaus Paulini, Maintal (DE); Peter (56) References Cited Schmidt, Schoeneck (DE); Silke Baasner, Schoeneck (DE); Emmanuel FOREIGN PATENT DOCUMENTS Polymeropoulos, Frankfurt (DE); WO WO O3051837 * 6, 2003 Eckhard Guenther, Maintal (DE); WO WO 2006005484 * 1, 2006 Michael Teifel, Weiterstadt (DE) OTHER PUBLICATIONS (73) Assignee: AEterna Zentaris GmbH, Frankfurt Kubinyi (3D QSAR in Drug Design: Ligand-Protein Interactions and (DE) Molecular Similarity, vol. 2-3, Springer, 1998, 800 pages), TOC, pp. 243-244 provided.* *) NotOt1Ce: Subjubject to anyy d1Sclaimer,disclai theh term off thisthi Tatsuta et al. (Bioorg. Med. Chem. Lett. 15 (2005) 2265-2269).* patent is extended or adjusted under 35 Wermuth, The Practice of Medicinal Chemsitry, 2d ed. (2003), 768 U.S.C. 154(b) by 852 days. pages, chs. 9-10 provided.* CAPLUS Abstract of WO O3051837.* (21) Appl. No.: 12/109,479 * cited by examiner (22) Filed: Apr. 25, 2008 (65) Prior Publication Data Primary Examiner — Robert Havlin (74) Attorney, Agent, or Firm — Oblon, Spivak, US 2009/O 170783 A1 Jul. 2, 2009 McClelland, Maier & Neustadt, L.L.P. Related U.S. Application Data (60) Provisional application No. 60/914,424, filed on Apr. (57) ABSTRACT 27, 2007. The present invention provides novel tetrahydrocarbazole compounds according to formula (I) as ligands of G-protein (30) Foreign Application Priority Data coupled receptors (GPCR) which are useful in the treatment and/or prophylaxis of physiological and/or pathological con Apr.
    [Show full text]
  • United States Patent (19) 11 Patent Number: 6,046,187 Berde Et Al
    US006046187A United States Patent (19) 11 Patent Number: 6,046,187 Berde et al. (45) Date of Patent: *Apr. 4, 2000 54) FORMULATIONS AND METHODS FOR 4,389,330 6/1983 Tice et al. .......................... 427/213.36 PROVIDING PROLONGED LOCAL 4,404,183 9/1983 Kawata et al. 424/19 ANESTHESIA 4,419,340 12/1983 Yolles ............. ... 424/19 4,434,153 2/1984 Urquhart et al. 424/22 (75) Inventors: Charles B. Berde, Brookline; Robert 4,479,911 10/1984 Fong - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 264/4.6 S. Langer, Newton, both of Mass.; 4,530,840 7/1985 Tice et al. ............................... 514/179 s s 4,542,025 9/1985 Tice et al. ................................. 424/78 Joanne Curley, San Jose, Calif.; Jenny 4,557,925 12/1985 Lindahl et al. ........................... 424/19 Castillo, Philadelphia, Pa. 4,568,535 2/1986 Loesche .................................... 424/19 4,568,536 2/1986 Kronenthal et al. 424/22 73 Assignee: Children's Medical Center 4,569,837 2/1986 Suzuki et al. ............................. 424/28 Corporation, Boston, Mass. 4,585,651 4/1986 Beck et al. ................................ 424/88 4,597,960 7/1986 Cohen ...... ... 424/28 * Notice: This patent issued on a continued pros- 4,622,219 11/1986 Haynes ...................................... 424/38 ecution application filed under 37 CFR 4,622,244 11/1986 Lapka et al. ....................... 427/213.32 1.53(d), and is subject to the twenty year 4,623.588 11/1986 Nuwayser et al. ................. 428/402.24 patent154(a)(2). term provisions of 35 U.S.C. ( List continued on next page.)page. FOREIGN PATENT DOCUMENTS 21 Appl.
    [Show full text]
  • Yerevan State Medical University After M. Heratsi
    YEREVAN STATE MEDICAL UNIVERSITY AFTER M. HERATSI DEPARTMENT OF PHARMACY Balasanyan M.G. Zhamharyan A.G. Afrikyan Sh. G. Khachaturyan M.S. Manjikyan A.P. MEDICINAL CHEMISTRY HANDOUT for the 3-rd-year pharmacy students (part 2) YEREVAN 2017 Analgesic Agents Agents that decrease pain are referred to as analgesics or as analgesics. Pain relieving agents are also called antinociceptives. An analgesic may be defined as a drug bringing about insensibility to pain without loss of consciousness. Pain has been classified into the following types: physiological, inflammatory, and neuropathic. Clearly, these all require different approaches to pain management. The three major classes of drugs used to manage pain are opioids, nonsteroidal anti-inflammatory agents, and non opioids with the central analgetic activity. Narcotic analgetics The prototype of opioids is Morphine. Morphine is obtained from opium, which is the partly dried latex from incised unripe capsules of Papaver somniferum. The opium contains a complex mixture of over 20 alkaloids. Two basic types of structures are recognized among the opium alkaloids, the phenanthrene (morphine) type and the benzylisoquinoline (papaverine) type (see structures), of which morphine, codeine, noscapine (narcotine), and papaverine are therapeutically the most important. The principle alkaloid in the mixture, and the one responsible for analgesic activity, is morphine. Morphine is an extremely complex molecule. In view of establish the structure a complicated molecule was to degrade the: compound into simpler molecules that were already known and could be identified. For example, the degradation of morphine with strong base produced methylamine, which established that there was an N-CH3 fragment in the molecule.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,617,114 B1 Fowlkes Et Al
    USOO6617114B1 (12) United States Patent (10) Patent No.: US 6,617,114 B1 Fowlkes et al. (45) Date of Patent: Sep. 9, 2003 (54) IDENTIFICATION OF DRUG OTHER PUBLICATIONS COMPLEMENTARYLIBRARIES COMBINATORIAL Bottger, et al., Identification- Y - of novel mam2 binding peptides by phage display, Oncogene, vol. 13, pp. 2141-2147, 1996. (75) Inventors: Dana M. Fowlkes, Chapel Hill, NC Lu, et al., Expression of Thioredoxin Random Peptide (US); Brian K. Kay, Madison, WI Libraries On the Escherichia coli Cell Surface as Functional (US); Jeffrey A. Frelinger, Chapel Hill, Fusions to Flagellin. A System Designed for Exploring NC (US); Robin Parish Protein-Protein Interactions, Biotechnology, vol. 13, pp. Hyde-Deruyscher, Chapel Hill, NC 366-372, Apr. 1995. (US) Valadon, et al., Peptide Libraries Define the Fine Specificity of Antipolysaccharide Antibodies to Cryptococcus neofor mans, J. Mol. Biol., vol. 261, pp. 11-22, 1996. (73) Assignee: Karo Bio AB, Huddinge (SE) Giebel, L. et al., “Screening of Cyclic Peptide Phage Librar ies Identifies Ligands that Bind Streptavidin with High (*) Notice: Subject to any disclaimer, the term of this Affinities”, Biochemistry 34:15430–15435 (1995). patent is extended or adjusted under 35 Kay, Brian K., et al., “An M13 phage library displaying U.S.C. 154(b) by 0 days. random 38-amino-acid peptides as a Source of novel sequences with affinity to seleted targets', Gene 128:59-65 (21) Appl. No.: 09/069,827 (1993). Lam, Kit S. et al., “A new type of Synthetic peptide library for identifying ligand-binding activity' Nature 354:82-84 (22) Filed: Apr. 30, 1998 (1991).
    [Show full text]
  • Supplementary Digital Content REVIEW of ANXIETY MODELS USED in 2010-2011. Type of the Study. Here We Cathegorize the Study Accor
    Supplementary digital content REVIEW OF ANXIETY MODELS USED IN 2010-2011. LEGEND Type of the study. Here we cathegorize the study according to its major aim or major finding as follows: anxiogenic effects, the compound had effects opposite to expectations; detection of anxiolytic effect, anxiolytic effects were noticed but no suggestion was formulated for use as anxiolytics; established anxiolytic, well-known anxiolytics studied for various reasons; no effect on anxiety, the compound did not fulfil expectations; mechanism, studies employing anxiolytic treatments but addressing developmental issues, neural mechanisms, drug interactions etc.; putative novel anxiolytic, the authors suggested the compound for anxiolytic drug development; (H), the tested compound was an herbal extract; (Ho), purified or synthesized compound of herbal origin. Anxiety tests. The tests listed in Table 1 were considered 'classical' for the reasons specified in the Abstract. Modifier. Tests are sometimes performed under unconventional conditions to induce heightened levels of anxiety and by this to icrease the translational value of the test. Procedures that altered (usually increased) anxiety levels normally shown in the given test were categorized as follows. chemical, hormonal or pharmacological treatments (e.g. ovarectomy, drug administration in adolescence, etc.); condition, modified testing conditions (e.g. high lighting, no habituation to the testing room, etc.); neural, treatments that affect neural functions (e.g. brain lesions, inhibited neurogenesis); selection, subjects from selection lines, specific strains, etc; stress, subjects exposed to stressors with long-lasting consequences (e.g. chronic immobility, drug withdrawal, etc); subject, the use of specific subjects classes (aged subjects, females, etc.); transgenic, the effects of drugs were studied in genetically engineered subjects.
    [Show full text]
  • UNITED STATES PATENT OFFICE 2,636,042 WATER-SOLUBLE HORMONE COMPOUNDS Ralph Salkin, Jackson Heights, N.Y., Assignor to S
    Patented Apr. 21, 1953 2,636,042 UNITED STATES PATENT OFFICE 2,636,042 WATER-SOLUBLE HORMONE COMPOUNDS Ralph Salkin, Jackson Heights, N.Y., assignor to S. B. Penick and Company, New York, N. Y., a corporation of Delaware No Drawing. Application July 8, 1949 Serial No. 103,759 5 Claims. (C. 260-39.4) 1. 2 My invention relates to an improvement in the ether, and the sulfate is then Salted out of the manufacture of water-soluble compounds of the aqueous solution by the addition of a, caustic estrane series, and in particular it is concerned solution under cooling. The liberated hormone With an improvement in the synthesis of alkali sulfate is extracted into a suitable Solvent, for and alkaline-earth metal salts of the sulfates of 5 instance butanol, pyridine being preferred how the estranes. ever. The hormone sulfate solution is exhaus The estranes to which my invention applies are tively extracted with ether to remove the solvent. steroids having a free hydroxyl group in the The resultant semicrystalline product is recrys 3-position and a hydroxy or keto group in the tallized from a dilute monohydric alcohol. Or 17-position of the molecule, such as estrone, O Water to give the pure sterol.ester. equilin, equilenin, estradiol and similar com In order to get pure ester Salts, I have found pounds. it essential that the tertiary amine-sulfur trioxide These products which are commonly known as adduct be absolutely pure when being reacted With conjugated estrogens can be obtained from nat the hormones. Improved yields and more readily ural sources such as the urine of pregnant mares purifiable light colored granular products result, or of stallions.
    [Show full text]
  • Download Product Insert (PDF)
    PRODUCT INFORMATION Semax Item No. 27719 CAS Registry No.: 80714-61-0 N Formal Name: L-methionyl-L-α-glutamyl- N H S L-histidyl-L-phenylalanyl-L- H2N prolylglycyl-L-proline O Synonym: ACTH4-7-PGP N H N N O MF: C37H51N9O10S O FW: 813.9 H N OH N O H Purity: ≥95% N O O O Supplied as: A solid H Storage: -20°C O HO Stability: ≥2 years Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis. Laboratory Procedures Semax is supplied as a solid. A stock solution may be made by dissolving the semax in the solvent of choice, which should be purged with an inert gas. Semax is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of semax in these solvents is approximately 5 and 1 mg/ml, respectively. Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of semax can be prepared by directly dissolving the solid in aqueous buffers. The solubility of semax in PBS, pH 7.2, is approximately 10 mg/ml. We do not recommend storing the aqueous solution for more than one day. Description Semax is a synthetic peptide analog of adrenocorticotropic hormone (ACTH) (4-10) (Item No. 27106) that has neuroprotective, analgesic, and anxiolytic properties.1-3 In vivo, semax (0.3 mg/kg) reduces cortical nitric oxide (NO) production and the number of neurological disturbances, such as seizures, falling, and twisting, in a rat model of global ischemia.1 It decreases acetic acid-induced writhing and nociception in a hind paw compression test in mice when administered at doses ranging from 0.015 to 0.5 mg/kg.2 Semax also increases time spent in the open arms in the elevated plus maze, indicating anxiolytic activity, in a rat model of maternal deprivation-induced anxiety.3 References 1.
    [Show full text]
  • Effects of Semax on Dopaminergic and Serotoninergic Systems of the Brain K
    Doklady Biological Sciences, Vol. 394, 2004, pp. 1–3. Translated from Doklady Akademii Nauk, Vol. 394, No. 1, 2004, pp. 130–132. Original Russian Text Copyright © 2004 by Eremin, Kudrin, Grivennikov, Miasoedov, Rayevsky. PHYSIOLOGY Effects of Semax on Dopaminergic and Serotoninergic Systems of the Brain K. O. Eremin*, V. S. Kudrin*, I. A. Grivennikov**, Academician N. F. Miasoedov**, and K. S. Rayevsky* Received June 11, 2003 Short-term effects of the synthetic nootropic peptide in rats and simultaneously raises the intracellular level Semax on the content and metabolism of monoamines of dopamine in the striatum [6]. in the brain of C57/Bl6 mice and Sprague–Dawley rats The goal of this study was to examine the effects of were studied. Intraperitoneal injection of Semax at a Semax on the neurochemical parameters of the dopam- dose of 0.15 mg/kg caused an increase in the tissue con- inergic and serotoninergic systems of the animal brain. centrations of 5-hydroxyindoleacetic acid (5-HIAA) in Semax was administered at a dose of 0.15 mg per kilo- the hypothalamus and striatum of mice 0.5 and 2 h after gram body weight to ë57/Bl6 mice, and their hypothal- the injection. Using brain microdialysis, we detected amus and striatum were analyzed for tissue levels of increased levels of extracellular 5-HIAA in the striatum dopamine (DA) and its metabolites 3,4-dihydroxyphe- of freely moving rats 1 h after administration of 0.15 or nylacetic acid (DOPAC) and homovanillic acid (HVA), 0.6 mg/kg Semax. The effect lasted for an additional as well as serotonin (or 5-hydroxytriptamine, 5-HT) 3 h.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • Tamoxifen As the First Targeted Long-Term Adjuvant Therapy for Breast
    V C Jordan Adjuvant tamoxifen therapy for 21:3 R235–R246 Review breast cancer Tamoxifen as the first targeted long-term adjuvant therapy for breast cancer Correspondence V Craig Jordan should be addressed to V C Jordan Departments of Oncology and Pharmacology, Lombardi Comprehensive Cancer Center, Georgetown University Email Medical Center, Washington, District of Columbia 20057, USA [email protected] Abstract Tamoxifen is an unlikely pioneering medicine in medical oncology. Nevertheless, the medicine Key Words has continued to surprise us, perform, and save lives for the past 40 years. Unlike any other " breast medicine in oncology, it is used to treat all stages of breast cancer, ductal carcinoma in situ,and " endocrine therapy male breast cancer and pioneered the use of chemoprevention by reducing the incidence of breast cancer in women at high risk and induces ovulation in subfertile women! The impact of tamoxifen is ubiquitous. However, the power to save lives from this unlikely success story came from the first laboratory studies which defined that ‘longer was going to be better’ when tamoxifen was being considered as an adjuvant therapy. This is that success story, with a focus on the interdependent components of: excellence in drug discovery, investment in self-selecting young investigators, a conversation with Nature, a conversation between the laboratory and the clinic, and the creation of the Oxford Overview Analysis. Each of these Endocrine-Related Cancer factors was essential to propel the progress of tamoxifen to evolve as an essential part of the fabric of society. Endocrine-Related Cancer (2014) 21, R235–R246 Introduction ‘Science is adventure, discovery, new horizons, insight into our and invariably unsuccessful (except for childhood world, a means of predicting the future and enormous power leukemia).
    [Show full text]
  • Labeling and Synthesis of Estrogens and Their Metabolites
    Labeling and Synthesis of Estrogens and Their Metabolites Paula Kiuru University of Helsinki Faculty of Science Department of Chemistry Laboratory of Organic Chemistry P.O. Box 55, 00014 University of Helsinki, Finland ACADEMIC DISSERTATION To be presented with the permission of the Faculty of Science of the University of Helsinki, for public criticism in Auditorium A110 of the Department of Chemistry, A. I. Virtasen Aukio 1, Helsinki, on June 18th, 2005 at 12 o'clock noon Helsinki 2005 ISBN 952-91-8812-9 (paperback) ISBN 952-10-2507-7 (PDF) Helsinki 2005 Valopaino Oy. 1 ABSTRACT 3 ACKNOWLEDGMENTS 4 LIST OF ORIGINAL PUBLICATIONS 5 LIST OF ABBREVIATIONS 6 1. INTRODUCTION 7 1.1 Nomenclature of estrogens 8 1.2 Estrogen biosynthesis 10 1.3 Estrogen metabolism and cancer 10 1.3.1 Estrogen metabolism 11 1.3.2 Ratio of 2-hydroxylation and 16α-hydroxylation 12 1.3.3 4-Hydroxyestrogens and cancer 12 1.3.4 2-Methoxyestradiol 13 1.4 Structural and quantitative analysis of estrogens 13 1.4.1 Structural elucidation 13 1.4.2 Analytical techniques 15 1.4.2.1 GC/MS 16 1.4.2.2 LC/MS 17 1.4.2.3 Immunoassays 18 1.4.3 Deuterium labeled internal standards for GC/MS and LC/MS 19 1.4.4 Isotopic purity 20 1.5 Labeling of estrogens with isotopes of hydrogen 20 1.5.1 Deuterium-labeling 21 1.5.1.1 Mineral acid catalysts 21 1.5.1.2 CF3COOD as deuterating reagent 22 1.5.1.3 Base-catalyzed deuterations 24 1.5.1.4 Transition metal-catalyzed deuterations 25 1.5.1.5 Deuteration without catalyst 27 1.5.1.6 Halogen-deuterium exchange 27 1.5.1.7 Multistep labelings 28 1.5.1.8 Summary of deuterations 30 1.5.2 Enhancement of deuteration 30 1.5.2.1 Microwave irradiation 30 1.5.2.2 Ultrasound 31 1.5.3 Tritium labeling 32 1.6 Deuteration estrogen fatty acid esters 34 1.7 Synthesis of 2-methoxyestradiol 35 1.7.1 Halogenation 35 1.7.2 Nitration of estrogens 37 1.7.3 Formylation 38 1.7.4 Fries rearrangement 39 1.7.5 Other syntheses of 2-methoxyestradiol 39 1.7.6 Synthesis of 4-methoxyestrone 40 1.8 Synthesis of 2- and 4-hydroxyestrogens 41 2.
    [Show full text]